Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
10.17
-0.24 (-2.31%)
At close: Jun 13, 2025, 4:00 PM
10.11
-0.06 (-0.59%)
After-hours: Jun 13, 2025, 7:21 PM EDT
Septerna Employees
Septerna had 75 employees as of December 31, 2024.
Employees
75
Change
n/a
Growth
n/a
Revenue / Employee
$13,027
Profits / Employee
-$1,054,773
Market Cap
453.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SEPN News
- 17 days ago - Septerna to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist - Seeking Alpha
- 4 weeks ago - Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash - Seeking Alpha
- 4 weeks ago - Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
- 4 weeks ago - Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - WSJ
- 4 weeks ago - Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters
- 4 weeks ago - Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases - GlobeNewsWire